are maintained regardless of acute changes in estimated glomerular filtration rate (eGFR) following treatment initiation in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

Diabetic kidney disease is chronic kidney disease that occurs as a complication of diabetes. Learn about its signs and ...

Doctors may use it to guide treatment decisions for people with mid to late stage chronic kidney disease (CKD ... treatment decisions than using eGFR alone. A person should also contact a ...

eGFR was also analyzed as a prospectively ... was investigated in the ADI CKD (adenine-induced animal model of chronic kidney disease) model, a well-established animal model of CKD.

"This decision not only validates the strength of the phase-III PROTECT study results but also reinforces our deep commitment to this rare kidney disease ... on the eGFR chronic slope endpoint ...

“This decision not only validates the strength of the Phase 3 PROTECT Study results but also reinforces our deep commitment to this rare kidney disease ... on the eGFR chronic slope endpoint ...

A1 indicates albuminuria category A1 (urine albumin/creatinine ratio <30 mg/g); A2, albuminuria category A2 (30–300 mg/g); A3, albuminuria category A3 (>300 mg/g); CKD, chronic kidney disease; GFR ...

IgAN is a progressive, rare kidney disease ... evaluates whether Vanrafia slows disease progression as measured by estimated glomerular filtration rate (eGFR) decline at week 136.

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation ...